;

This content has been developed by Galderma and is intended for Healthcare Professionals Only

Prescribing information for Aklief®▼ (trifarotene) is available by clicking this link.

AKLIEF® is a topical retinoid indicated for the cutaneous treatment of moderate acne vulgaris of the face and/or trunk in patients from 12 years of age and older when many comedones, papules and pustules are present.5

AKLIEF® delivers trifarotene, which has 20x greater affinity for RAR-γ, the most common retinoid receptor in the skin, compared to RAR-α and RAR-β. The clinical relevance of this is unknown.6-8

Randomised controlled trial data show that AKLIEF® significantly reduced inflammatory and noninflammatory facial and truncal acne lesions at week 12 vs baseline.6*

IGA success rates†: 29.4% vs 19.5% vehicle cream

54.4%‡ fewer IL facial lesions vs 44.8% vehicle cream
49.7%‡ fewer NIL facial lesions vs 35.7% vehicle cream

Accelerates skin-cell turnover

by decreasing cell adhesion and promoting keratinocyte differentiation and modulation of desquamation.9

Aids in skin hydration

by allowing the skin to transport and retain water more efficiently, strengthening the skin barrier.9

Refines skin

by down-regulating genes involved in the breakdown of collagen and elastin, protecting their presence even as skin ages.9,10

The clinical relevance of this is unknown.9

Truncal acne (chest, shoulders, back) affects around half of people with acne9

Data from a US study showed that 52% of 696 patients with acne vulgaris had truncal involvement.10

Data from a Canadian study of 965 patients with acne showed that the following areas were most commonly affected11:

AKLIEF® provides an alternative treatment to antibiotic therapy for acne.


See a visible difference

Subject photographs from the PErFEct 1 study4**

IL = 27, NIL = 29 & IL = 1, NIL = 5

PErFEct: Pivotal Efficacy FacE Trunk IL = 27, NIL = 29 & IL = 1, NIL = 5

AKLIEF® is generally well tolerated.5

The most commonly reported adverse reactions were application site irritation, application site pruritus and sunburn.5
AKLIEF® is contraindicated during pregnancy or for women planning a pregnancy.5

These cutaneous reactions are very common and of mild, moderate and severe intensity for up to 39%, 29.7% and 6.2% of patients, respectively on the face.5

On the trunk, up to 32.9%, 18.9%, 5.2% of patients had mild, moderate and severe reactions respectively. The maximum severity typically occurred
at Week 1 for the face, and at Week 2 to 4 for the trunk, and decreased with
continued use of the medication.5

Shop now

*PIVOTAL Study 1 results vs baseline at Week 12
** Representative of study population with photos during study
† P less than 0.001 versus vehicle cream
‡ % of subjects with an IGA score of clear (0) or almost clear (1) and at least a 2-grade improvement from baseline to Week 12

IGA: Investigator Global Assessment; IL: Inflammatory lesion; NIL: non-inflammatory lesion; PGA: Physician Global Assessment; RAR-α: retinoic acid receptor alpha; RAR-β: retinoic acid receptor beta; RAR-γ: retinoic acid receptor gamma.

References: 1. Kasser M et al. J Cosmet Dermatol. 2020;00:1–6. 2. Stein Gold L et al. Why We Should Consider Evidence-Based Treatment Options for Truncal Acne. Dermatol Ther (Heidelb) 2021;11:661–664. 3. Blume-Peytavi U et al. Long-term safety and efficacy of trifarotene 50 μg/g cream, a first-in-class RAR-γ selective topical retinoid, in patients with moderate facial and truncal acne. JEADV 2020, 34, 166–173. 4. Bell K et al. Tretinoin 0.1% and Benzoyl Peroxide 3% Cream for the Treatment of Facial Acne Vulgaris. Annals of Pharmacotherapy 2021;55(1) 111–116. 5. Aklief Cream Summary of Product Charactistics. Available at: https://www.medicines.org.uk/emc/ product/13881/smpc#gref. Accessed: February 2025. 6. Tan J et al. Randomized phase 3 evaluation of trifarotene 50g/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019 Jun;80(6):1691-1699. 7. Aubert J et al. Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptoragonist trifarotene. Br J Dermatol. 2018 Aug;179(2):442-456. 8. Fisher GJ et al. Immunological Identification and Functional Quantitation of Retinoic Acid and Retinoid X Receptor Proteins in Human Skin. JBC 1994;269;32:20629-20635. 9. Cosio T et al. Trifarotene: A Current Review and Perspectives in Dermatology. Biomedicines 2021, 9(3), 237; https://doi.org/10.3390/biomedicines9030237. 10. Zasada M, Budzisz E. Retinoids: active molecules influencing skin structure formation in cosmetic and dermatological treatments. Postepy Dermatol Alergol. 2019 Aug 30;36(4):392–397. doi: 10.5114/ada.2019.87443. 11. Tan J, Beissert S, Cook-Bolden F, Chavda R, Harper J, Hebert A, Lain E, Layton A, Rocha M, Weiss J, Dréno B. Impact of facial and truncal acne on quality of life: A multi-country population-based survey. JAAD Int. 2021;3:102- 110. 12. Del Rosso JQ, Bikowski JB, Baum E, Smith J, Hawkes S, Benes V, Bhatia N. A closer look at truncal acne vulgaris: prevalence, severity, and clinical significance. J Drugs Dermatol. 2007;6(6):597-600. 13. Tan J et al. Prevalence and severity of facial and truncal acne in a referral cohort. J Drugs Dermatol. 2008;7(6):551-6. 14. UK Data on File 015 - Subject photographs from Study 18251

 

Adverse events should be reported. For the UK, Reporting forms and information can be found at
www.mhra.gov.uk/yellowcard or search for Yellow Card in the Google Play or Apple App Store.

For Ireland, Suspected adverse events can be reported via HPRA Pharmacovigilance, Website:
www.hpra.ie; Adverse events should also be reported to Galderma (UK) Ltd,
Email: medinfo.uk@galderma.com Tel: +44 (0) 300 3035674


UKI-AFC-2400004 I March 2025